The Relationship Between Serum and Urinary Angiotensinogen Levels and Long-Term Renal Prognosis in Acute Renal Injury (Renal Injury)

March 30, 2026 updated by: ALİ AKIN, Sanliurfa Mehmet Akif Inan Education and Research Hospital
This study aims to retrospectively examine long-term (at the end of the 3rd year) renal function in the thesis study titled "Investigation of serum and urine angiotensinogen levels as a prognostic indicator of renal function in acute kidney injury," which received approval from the Tokat Gaziosmanpaşa University Faculty of Medicine ethics committee in 2019 (approval number 19-KAEK-052). Thus, the relationship between serum and urine angiotensinogen levels and long-term renal function will be investigated, and the importance of this biomarker in the development of chronic kidney disease (CKD) in patients with acute kidney injury (AKI) will be examined.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Şanlıurfa
      • Karaköprü, Şanlıurfa, Turkey (Türkiye), 6300
        • Mehmet Akif İnan Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

PATIENTS DEVELOPING KIDNEY FAILURE

Description

Inclusion Criteria:

  • PATIENTS DEVELOPING KIDNEY FAILURE

Exclusion Criteria:

  • MALIGNANT PATIENTS

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The relationship between serum and urinary angiotensinogen levels and renal function at the end of the 3rd year in patients who developed acute kidney injury.
Time Frame: Patients admitted to intensive care and who developed renal failure between January 2018 and January 2020.
serum and urinary angiotensinogen levels
Patients admitted to intensive care and who developed renal failure between January 2018 and January 2020.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The relationship between serum and urinary angiotensinogen levels and renal function at the end of the 3rd year in patients who developed acute kidney injury.
Time Frame: Patients who were alive after 2020 and whose kidney function tests were measured at the end of the 3rd year.
serum and urinary angiotensinogen levels
Patients who were alive after 2020 and whose kidney function tests were measured at the end of the 3rd year.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sanliurfa Mehmet Akif Inan Education and Research Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2026

Primary Completion (Actual)

March 1, 2026

Study Completion (Actual)

March 1, 2026

Study Registration Dates

First Submitted

March 11, 2026

First Submitted That Met QC Criteria

March 30, 2026

First Posted (Actual)

April 6, 2026

Study Record Updates

Last Update Posted (Actual)

April 6, 2026

Last Update Submitted That Met QC Criteria

March 30, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 26-MOBAEK-071

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

THE DATA IS PATIENT-SPECIFIC AND THEREFORE CANNOT BE SHARED.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on In Acute Kidney Injury

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe